Table 2 RNA based biomarkers used in follow-up for non muscle invasive bladder cancer patients
Reference | Patients/samples | Recurrence rate | Sensitivity | Specificity | NPV | PPV | AUC | Method | Markers |
|---|---|---|---|---|---|---|---|---|---|
Sapre et al 2016 [29] | 131/131 | NA | 88 | 48 | 75 | 63 | 0.74 | miRNA PCR | 6 miRNA signaturea |
Kavalieris et al 2017 [30] | 736/1036 | 15.1% | 92 | NA | 96 | NA | 0.73 | mRNA PCR | 5 genes mRNA expression (Cx Bladder Monitor® )b |
Lotan et al 2017 [31] | 748/1016 | 14.8% | 91 95 (HG) | NA | 96 | NA | NA | mRNA PCR | 5 genes mRNA expression (Cx Bladder Monitor® )b vs NMP22 ELISA vs NMP22 BladderChek |
Pilcher et al 2018 [32] | 140/155 | 30.7% | 84 100 (HG) | 91 | 93 | 72 | 0.87 | mRNA RT-PCR | ABL1, CRH, IGF2, UPK1B, ANXA10 (Xpert Bladder Cancer Monitor®) |
Wallace et al 2018 [33] | 370/370 | 13.2% | 73 83 (HG) | 77 | 92 | 44 | 0.87 | mRNA RT-qPCR | ABL1, CRH, IGF2, ANXA10, UPK1B (Xpert Bladder Cancer Monitor®) |